Beijing: China's vaccines for the COVID-19 pandemic will be available and affordable to people worldwide, said Liu Jingzhen, chairman of China National Pharmaceutical Group, in Beijing on Thursday.
A ceremony took place in Beijing on Thursday to launch phase three clinical trials for a COVID-19 vaccine in Peru. Peru's national health authorities have approved the trials, the latest in China's efforts to strengthen international cooperation in pandemic control. "We launched the promotion of international clinical trials in April. So we’re making key breakthroughs in the United Arab Emirates, which have been very successful. Today, we established a cooperation relationship with Peru, and officially received the documents in all aspects, and will soon start equity participation. Up to now, the clinical phase three trials, from the experimental point of view, the layout is completely sufficient," said Liu.
Liu said that China's Biotec Group is carrying out the research with experts from some of Peru's leading universities. "In Peru, we're working with the National University of San Marcos and another university [University of Cayetano Heredia], specifically to cooperate comprehensively on the clinical phase three trials. They're two of the top universities in Peru, and their experts have been very professional across the board," said Liu.
Liu added that the vaccines will only be used after sufficient preparations and they are striving to make it available to the public worldwide. "Vaccines are to be used for prevention by healthy people. It must be accessible to the general public. According to President Xi Jinping's speech at the World Health Assembly, China's vaccines will be used as global public goods after research and development is successful, which means both available and affordable to the people worldwide," Liu said.
Liu pointed out two research and production facilities in Beijing and Wuhan, which was hit the hardest by the virus, that could ensure the supply of 200 million vaccines a year. "We have two research and production facilities in Beijing and Wuhan, which can ensure the next large-scale quantitative production, feasibility and availability of the vaccines. We are making every effort to prepare for the vaccine's mass production. According to normal daytime production speed, we can supply over 200 million vaccines a year. We can ensure the availability and mass production on the basis of the quality, safety, and effectiveness of our vaccines," said Liu.
Liu introduced that taking an injection twice with an interval of 28 days would give the best effect of the vaccines. "According to our clinical experiments, taking two injections can achieve the best effect. The best interval between the two injections is 28-days, which would ensure overall effectiveness, because, after the first injection, the antibody would increase slowly and after the second injection, the antibody increases quite fast. The two injections could guarantee the validity and could prolong the validity. So this method is best in effectiveness, which is approved by experimental data," said Liu.
No comments:
Post a Comment